TCR‐T cells are genetically engineered to express specific TCRs targeting intracellular antigens presented on MHC molecules, allowing TCR‐T therapy to attack a broader range of tumor‐specific antigens and showing promising potential in solid tumors. Here, HLA-C is linked to neoplasm.